Standards of Care in Diabetes, Part 3

The 2023 CME/CE course on diabetes diagnosis and management, a part of the Type I & II diabetes patient treatment series, provides comprehensive insights into contemporary practices for managing this chronic condition. With the increasing global burden of diabetes, especially Type 2, healthcare professionals must remain up to date on the latest advancements in diagnostics, pharmacologic therapies, and patient-centered treatment strategies. This course presents expert-led discussions on diagnostic criteria, HbA1c targets, and risk assessment models. Participants will acquire critical skills in evaluating pharmacological and non-pharmacological treatment approaches, including the latest antidiabetic medications, insulin regimens, and technologies such as continuous glucose monitoring and insulin pumps. Emphasis is also placed on lifestyle modification, obesity management, and integrating cardiovascular risk reduction into diabetes care. This program is designed to empower providers with practical tools and evidence-based strategies to optimize glycemic control and improve patient outcomes.

Educational Objectives

• Recognize obesity and weight management strategies for the prevention of type 2 diabetes.
• List the pharmacologic approaches to glycemic treatment.
• Describe cardiovascular disease and associated risk management strategies in diabetic patients.

The estimated time to complete this activity is 1 hour.

Who Should Do This Course

This course is specifically designed for Physicians, Nurse Practitioners, Physician Assistants, and Nurses involved in the care of patients with diabetes or at risk for developing the condition. It is particularly beneficial for healthcare professionals practicing in the fields of Family Medicine, Endocrinology, Internal Medicine, General Practice, Primary Care, Cardiology, and Geriatrics.

Did You Know?

• Over 37 million people in the U.S. have diabetes, and approximately 1 in 5 of them do not know they have it (CDC, 2023).
• Obesity is a major modifiable risk factor for Type 2 diabetes, with lifestyle interventions shown to reduce incidence by up to 58% (Diabetes Prevention Program Research Group).
• Cardiovascular disease is the leading cause of death among individuals with diabetes, accounting for more than 50% of fatalities (ADA, 2022).
• SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular benefits beyond glucose control in major clinical trials (EMPA-REG, LEADER).
• The global cost of diabetes-related healthcare is expected to surpass $845 billion annually by 2045 (International Diabetes Federation, 2022).